Printer Friendly

CYTRX CORPORATION ANNOUNCES THE INITIATION OF PHASE II STUDY SITES OF RHEOTHRX(R) INJECTION

 CYTRX CORPORATION ANNOUNCES THE INITIATION
 OF PHASE II STUDY SITES OF RHEOTHRX(R) INJECTION
 NORCROSS, Ga., Feb. 20 /PRNewswire/ -- CytRx Corporation (NASDAQ: CYTR) announced today that it has been advised by Burroughs Wellcome Co. of the initiation of Phase II study sites investigating RheothRx(R) Injection in myocardial infarction and sickle cell crisis.
 The study sites are currently awaiting the enrollment of patients in both studies. Burroughs Wellcome Co. licensed RheothRx(R) Injection from CytRx in April 1990.
 CytRx Corporation is a biopharmaceutical company engaged in the research and development of therapeutics incorporating copolymers. The company is developing human pharmaceutical products intended for use in the treatment of vascular, immune system and infectious diseases as well as burns. The company is also developing adjuvants for use in both human and veterinary vaccines and is currently marketing Hunter's TiterMax(TM), an immunoadjuvant for use by the basic research community.
 Burroughs Wellcome Co. is a research-based pharmaceutical company with headquarters in Research Triangle Park, N.C. The company is a wholly on?ed subsidiary of The Wellcome Foundation Ltd. of London.
 -0- 2/20/92
 /CONTACT: CytRx Corporation public relations, 404-368-9500/
 (CYTR) CO: CytRx Corporation; Burroughs Wellcome Co. ST: Georgia IN: MTC SU:


BR-BN -- AT007 -- 4070 02/20/92 11:08 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 20, 1992
Words:210
Previous Article:BAYBANKS ANNOUNCES EXPANSION OF COMMUNITY INVESTMENT PROGRAM
Next Article:KOCH ANNOUNCES MAJOR EXPANSION OF CORPUS CHRISTI REFINERY
Topics:


Related Articles
CYTRX CORPORATION ANNOUNCES THE BEGINNING OF PHASE II TRIALS OF RHEOTHRX(R) INJECTION
CYTRX CORPORATION ANNOUNCES PHASE II TRIALS OF RHEOTHRX(R) INJECTION FOR SICKLE CELL
CYTRX CORPORATION ANNOUNCES PHASE II TRIALS OF RHEOTHRX(R) INJECTION FOR SICKLE CELL
FIRST OF TWO RHEOTHRX(R) STUDIES REPORTED: 9,000-PATIENT PHASE III STUDY IN ACUTE MYOCARDIAL INFARCTION PLANNED
NEW DATA DEMONSTRATE THAT RHEOTHRX(R) MAY ENHANCE ACTION OF THROMBOLYTICS IN TREATING HEART ATTACKS
NEW DATA DEMONSTRATE THAT RHEOTHRX MAY ENHANCE ACTION OF THROMBOLYTICS IN TREATING HEART ATTACKS
CYTRX ANNOUNCES RHEOTHRX(R) INJECTION PHASE III TRIAL INITIATION
CYTRX ANNOUNCES RHEOTHRX PHASE II MITI TRIAL ENDS
CYTRX: RHEOTHRX HEART ATTACK STUDY ONGOING
CYTRX ANNOUNCES EVALUATION OF RHEOTHRX INJECTION TO ENHANCE CANCER TREATMENT EFFECTIVENESS

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters